Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases

Howard E. Gendelman, Vellareddy Anantharam, Tatiana Bronich, Shivani Ghaisas, Huajun Jin, Anumantha G. Kanthasamy, Xinming Liu, Jo Ellyn McMillan, R. Lee Mosley, Balaji Narasimhan, Surya K. Mallapragada

Research output: Contribution to journalReview article

60 Scopus citations

Abstract

Interest in nanoneuromedicine has grown rapidly due to the immediate need for improved biomarkers and therapies for psychiatric, developmental, traumatic, inflammatory, infectious and degenerative nervous system disorders. These, in whole or in part, are a significant societal burden due to growth in numbers of affected people and in disease severity. Lost productivity of the patient and his or her caregiver, and the emotional and financial burden cannot be overstated. The need for improved health care, treatment and diagnostics is immediate. A means to such an end is nanotechnology. Indeed, recent developments of health-care enabling nanotechnologies and nanomedicines range from biomarker discovery including neuroimaging to therapeutic applications for degenerative, inflammatory and infectious disorders of the nervous system. This review focuses on the current and future potential of the field to positively affect clinical outcomes.

Original languageEnglish (US)
Pages (from-to)751-767
Number of pages17
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume11
Issue number3
DOIs
StatePublished - 2015

Keywords

  • Diagnostics
  • Drug development
  • Nanoneuromedicine
  • Nanotechnology
  • Neurodegenerative disorders

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases'. Together they form a unique fingerprint.

  • Cite this